Valoración del efecto del tratamiento prolongado con âcido valproico sobre los nivelés plasmáticos de carnitina, amonio y aminoâcidos relacionados con el ciclo de la urea en pacientes epilépticos pediâtricos

Revista de Neurologia

Volumn 25, Issue 143, 1997, Pages 1037-1044

  Navarro Quesada, F J ^a,c   Lluch Fernandez M D ^a   Vaquero Abellan M ^a   Marchante Serrano, C ^b   Jimenez C ^b  

^a Unidad de Neurologia Infantil   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c NONE   (Spain)

Author keywords

Carniline; Child; Epilepsy; Hiperamoniemia; Hyperammoniemia; Urea cycle; Valproic acid

Indexed keywords

AMINO ACID; AMMONIA; ANTICONVULSIVE AGENT; CARNITINE; GLUTAMINE; GLYCINE; ORNITHINE; UREA; VALPROIC ACID;

ADOLESCENT; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; EPILEPSY; HUMAN; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; AMMONIA BLOOD LEVEL; ANTICONVULSANT THERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY;

ADOLESCENT; AMINO ACIDS; AMMONIA; ANTICONVULSANTS; CARNITINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; GLUTAMINE; GLYCINE; HUMANS; INFANT; INFANT, NEWBORN; ORNITHINE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UREA; VALPROIC ACID;

EID: 0031179762     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. cr Curso de Formaciôn Continuada. Madrid: Acciôn Médica, 1990; 30-4.
2. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance ofdivalproe.x sodium. Neurology 1983; 33: 808-11.
3. Committee On Drugs. Valproic Acid: benefits and risks. Pediatrics 1982; 70:316-9.
4. Coulter D. Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1984; 689.
5. McGarry D, Foster D. Systemic carnitine deficiency. NEJ Med 1980; 303: 1413-4.
6. Bieber LL. Carnitine. Ann Rev Biochem 1988; 57:261-83.
7. Karpati G, Karpenter S, Engel A, et al. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and patho-physiologic features. Neurology 1975; 25: 16-24.
8. Chapoy P, Angelini C, Brown J, et al. Systemic carnitine deficiency. A tratable inherited lipid-storage disease presenting as Reye's Syndrome, NEJ Med 1980; 303: 1389-93.
9. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammoncmia associated with valproic acid therapy. J Pediatr 1982; 101: 782-5.
10. Carrier H, Berthiller G. Carnitine levels in normal children and adults and in patients with diseased muscle. Muscle & Nerve 1980; 3:326-34.
11. Beghi E, Bizzi A,'Codegoni AM, The Collaborative Group For The Study Of Epilepsy. Valproate, carnitine metabolism, and biochemical indicators of liver function. Epilepsia 1990; 31: 346-52.
12. Murphy J, Marquardt K, Shug A. Valproic acid associated abnormalities of carnitine metabolism. Lancet 1985; 820-1.
13. Rodrigo E, Novo I, Castro Gago M, et al. Estudio clínico-experimental sobre la repercusión del ácido valproico a nivel del metabolismo de la carnitìna y del ciclo de la urea. Premios Nestlé Nutrición Infantil 1991. Barcelona: Ancora SA., 1992; 151-97.
14. Rodríguez Segade S, de la Pena ÇA, Tutor JC, et al. Carnitine deficiency associated with anticonvulsant therapy. Clin Chim Acta 1989; 181: 175-81.
15. Ohtani Y, Ohyanagi K, Yamamoto S, et al. Secondary carnitine deficiency in hyperammonemic attacks of omithine transcarbamylase deficiency. J Pediatr 1988; 112:409-14.
16. Monta J, Yoshino M, Yuge K. Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs. Neuropediatrics 1986; 17:203-5.
17. Shapira Y, Gutman A. Muscle carnitine deficiency in patients using valproic acid. J Pediatr 1991; 118:646-9.
18. Riva R, Albani F, Gobbi G, et al. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993; 34: 184-7.
19. linuma K, Hayasaka K, Narisawa K, et al. Hyperamino-acidemia and hyperammonaemia in epileptic children treated with valproic acid. Eur J Pediatr 1988; 148:267-9.
20. Rao M, Stefan H, Scheid C, et al. Serum amino acids, liver status, and antiepileptic drug therapy in epilepsy. Epilepsia 1993; 34: 347-54.
21. O'Connor J, Costell M, Minguez M, et al. Effect of L-Carnitine on ketone bodies, redox state and free amino acids in the liver of hyperammonemic mice. Biochem Pharmacol 1987; 36:3169-73.
22. Castro Gago M, Rodrigo E, Marwan K, et al. Efecto de la administración aguda de âcido valproico sobre el metabolismo de la carnitina y del amonio a nivel sanguineo. Rev Esp de Epilepsia 1990; 5: 86-90.
23. Verity C, Applegarth D, Parrell K, Kirby L. The influence of anti-convulsants on fasting plasma ammonia and amino acid levels. Clin Biochem 1983; 16:344-5.
24. Haines J, Rich S, Tsai M, Anderson V. Altered amino acid levels in multiply affected subships with seizures. Epilepsia 1985; 26: 642-648.
25. Haidukewych D, John G, Zielinski J, Rodin E. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia. Ther Drug Monitor 1985; 7: 290-4.
26. Monaco F, Mutani R, Durelli L, Delsedime M. Free amino acids in serum of patients with epilepsy: significant increase in taurine. Epilepsia 1975; 16:245-9.
27. Zaccara G, Campostrini R, Paganini M, et al. Long-term treatment with sodium valproate: monitoring of venous ammonia concentrations and adverse effects. Ther Drug Monit 1987; 9: 34-40.
28. Nieto Barrera M. Convulsiones febriles. En Sociedad de Pediatría de Andalucía Occidental y Extremadura, ed. Monografias (IV). Convulsiones fébriles. Cordoba 1993; 9-63.
29. Herranz Femández JL. Valoración de los fármacos antiepilépticos. En Epilepsia: 2° Curso de Formación Continuada. Madrid: Acción Médica, I99I;28-35
30. Oberholzer V, Briddon A. A novel use of amino acid ratios as an indicator of nutritional status. En Lubec G, Rosenthal G, eds. Escom Science Publishers SV. Amino Acids. Chemistry, Biology and Medicine 1990; 1079-83.
31. Melegh B, Kerner J, Acsadi G, et al. L-Carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 1988; 21: 40-3.
32. Thorn H, Carter PE, Cole GF, Stevenson KL. Ammonia and camitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev. Med Child Neurol 1991: 33: 795-802.
33. Camina MF, Rozas I, Castro Gago M, et al. Alteration of renal camitine metabolism by anticonvulsant treatment. Neurology 1991; 41: 1444-8.
34. Camina MF, Rozas I, Gómez M, et al. Short-term effects of administration of anticonvulsant drugs on free camitine and acylcamitine in mouse serum and tissues. BrJPharmacol 1991; 103: 1179-83.
35. Holme E. Camitine deficiency induced by pivampicillin and pivmccillinam therapy. Lancet 1989; 2:469-73.
36. Morrow G, Barness L. Studies in a patient with methylmalonic acidemia. JPediatr 1969; 74:691-8.
37. Hommes F, Roesel R. Studies on a case of HHH-Syndrome (Hypcrammonemia, Hyperornithinemia, Homocitrullinuria). Neuropediatrics 1986; 17:48-52.
38. Opala G, Winter S, Vance C, et al. The effect of valproic acid on plasma camitine levels. Am J Dis Child 1991; 145: 999-1001.
39. Hug G, McGraw C, Bates S, Landrigan E. Reduction of serum camitine concentrations during anticonvulsant therapy with phenobarbi-tal, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991 ; 119: 799-802.
40. Melegh B. Camitine supplementation in pivampicillin treatment. Lancet 1989; 2: 1096.
41. Kelley R. Papel del suplemento de carnitina en el tratamiento con ácido valproico. Pediatrics (ed. esp.) 1994; 37: 345-6.
42. Freeman J, Vining E, Cost S, Singhi P. La administración de carnitina £mejora los sintomas atribuidos a los fármacos anticonvulsivantes? Un estudio cruzado doble ciego. Pediatrics (ed. esp.) 1994; 16:405.
43. Riva R, Zaccara G, Albani F, et al. Effects of acute valproic acid administration on camitine plasma concentrations in epileptic patients. Epilepsy Res 1991; 8: 149-52.
44. Bartlett K. Sodium valproate and hyperglycinaemia. Lancet 1977; 716.
45. Jacken J, Corbeel L, Casaer P,-et al. Dipropylacetate (valproate) and glycine metabolism. Lancet 1977; 617.
46. Coulter D. Valproate, hyperamonaemia and hyperglycinaemia. Lancet 1980; 260.
47. Morrow G, Barnes L, Auerbach V, et al. Observations on the coexistence of methylmalonic acidemia and glycinemia. J Pediatr 1969; 74: 680-90.
48. Cederblad G, Lindstedt S. Excretion of L-carnitine in man. Clin Chim Actal971;33: 117-123.
49. Stephens J, Levy R. Effects of valproate and citrulline on ammoniuminduced encephalopathy. Epilepsia 1994; 35: 164-71.
50. Laub MC. Nutritional influence on serum ammonia in young patients receiving sodium valproate. Epilepsia 1986; 27: 55-9.
51. Coulter D, Alien R. Hyperammonemia with valproic acid therapy. J Pediatr 1981; 99: 317-9.
52. Galdi AP, Clark JB. An unusual case of camitine palmitoyl transferase deficiency. Arch Neurol 1989; 46: 819-20.
53. Coulter D, Alien R. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy. Lancet 1980; 1310-1.
54. Castro Gago M, Bemabeu FA, Novo F, et al. Efecto de los fármacos anticomiciales sobre el metabolismo renal de la carnitina. Rev Neurol 1994; 22:646-50.